Gsk573719, a long-acting muscarinic antagonist of GlaxoSmithKline, was approved for clinical use in China
-
Last Update: 2015-01-20
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
At present, the clinical application of GSK's long-acting muscarinic antagonist gsk573719 (umeclidinium) has left the task sequence of supplementary data, and was approved on January 14, 2015 Recently, the status is "under approval" Umeclidinium is a new single drug therapy for COPD As a daily bronchodilator, umeclidinium can affect the muscles around the respiratory tract and prevent muscle contraction On April 28, 2014, umeclidinium was approved for listing in the European Union (the product name is Incruse), which is the first time that umeclidinium has been approved in the world At present, the registration and application of GSK in China has also made new progress, and GSK will soon start clinical trials in China.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
